Rajeev M. Shah
CIK 1619841 · last filed 2026-09-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.13B
Companies
41
Total Filings
114
Lifetime Open-Market Net
$4.54B
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PBLS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestOfficerDirector10% owner* stale (no filing in 3 yrs)
Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Reported Address
200 BERKELEY STREET18TH FLOOR
BOSTON, MA 02116
Related Filers
RA CAPITAL MANAGEMENT, L.P. — 357 joint filings, latest 2026-09-17
Peter Kolchinsky — 351 joint filings, latest 2026-09-17
RA Capital Healthcare Fund LP — 341 joint filings, latest 2026-09-17
RA Capital Nexus Fund II, L.P. — 97 joint filings, latest 2026-07-22
RA Capital Nexus Fund, L.P. — 89 joint filings, latest 2026-09-17
RA Capital Nexus Fund III, L.P. — 57 joint filings, latest 2026-08-14
Inhibrx, Inc. — 2 joint filings, latest 2020-08-24
Inozyme Pharma, Inc. — 2 joint filings, latest 2020-07-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TYRA | Director | 10,127,311 | $21.27 | $215.46M | $8.32M | 2 | 2026-09-17 |
| ARTV | Director | 68,320 | $4.22 | $288.3K | $2.92M | 3 | 2026-09-08 |
| IKT | 10%+ Owner | 6,970,000 | $1.55 | $10.84M | $0 | 1 | 2026-07-31 |
| ACRV | Director | 9,366 | $1.71 | $16.0K | $211.84M | 3 | 2026-06-22 |
| HOWL | Director | 341,353 | $1.01 | $344.8K | $111.50M | 3 | 2026-06-16 |
| PBLS | Director | 26,285,093 | $26.37 | $693.14M | $2.12B | 2 | 2026-06-15 |
| Climb Bio, Inc. (ELYM) Delisted | Director | 2,866,375 | $5.11 | $14.65M | $5.28M | 6 | 2026-06-08 |
| COAG | Director | 6,372,170 | $37.63 | $239.82M | $313.97M | 2 | 2026-05-14 |
| ACET | 10%+ Owner | 932,624 | $3.93 | $3.67M | $0 | 1 | 2026-04-29 |
| PRLD | 10%+ Owner | 6,475,882 | $3.81 | $24.67M | $0 | 1 | 2026-04-28 |
| VOR | Director | 3,936,436 | $18.31 | $72.08M | -$82.92M | 4 | 2026-04-10 |
| ABOS | Director | 19,103,785 | $2.23 | $42.70M | $350.00M | 4 | 2026-03-18 |
| SGP | Director | 2,054,678 | $30.70 | $63.08M | $295.20M | 1 | 2026-02-11 |
| FULC | 10%+ Owner | 8,852,079 | $3.67 | $32.49M | -$233.41M | 2 | 2025-12-10 |
| WVE | Director | 28,815 | $3.37 | $97.0K | $20.00M | 3 | 2025-08-13 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 3,365,523 | $221.38 | $745.06M | $400.00M | 2 | 2025-06-30 |
| SPRY | Director | 902,904 | $3.83 | $3.46M | $116.25M | 3 | 2025-06-27 |
| NKTX | Director | 754,311 | $1.65 | $1.24M | $0 | 2 | 2025-06-09 |
| JANX | Director | 10,031,081 | $17.29 | $173.44M | $326.71M | 2 | 2025-03-07 |
| 89bio, Inc. (ETNB) Delisted | Director | 4,965,769 | $14.84 | $73.69M | $31.91M | 5 | 2024-11-18 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | 0 | $1.10 | $0 | $20.00M | 5 | 2023-06-08 |
| BDTX | Director | 311,926 | $1.73 | $538.1K | $19.00M | 7 | 2023-05-17 |
| MLYS | Director | — | $20.69 | — | $0 | 1 | 2023-02-13 |
| CTKB | Director | 12,459,692 | $5.92 | $73.70M | $69.40M | 2 | 2022-03-11 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | 28,207 | $93.80 | $2.65M | $195.00M | 1 | 2021-07-06 |
| SLDB | Director | 772,019 | $6.13 | $4.73M | $66.75M | 10 | 2021-06-21 |
| KALA | Director | 4,370 | $0.19 | $809 | $78.00M | 8 | 2021-06-21 |
| PHAT | 10%+ Owner | 3,115,008 | $6.04 | $18.83M | -$124.25M | 1 | 2021-03-15 |
| Iterum Therapeutics plc (ITRM) Delisted | 10%+ Owner | 776,773 | $0.03 | $23.3K | $0 | 1 | 2021-02-08 |
| DYN | 10%+ Owner | 2,805,045 | $16.67 | $46.76M | $37.62M | 1 | 2020-09-23 |
| TGTX | 10%+ Owner | 12,629,868 | $56.43 | $712.70M | -$12.28M | 1 | 2020-09-11 |
| INBX | 10%+ Owner | 2,129,003 | $95.24 | $202.77M | $0 | 1 | 2020-08-24 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 4,417,259 | $10.15 | $44.84M | $81.22M | 1 | 2020-07-29 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 1,403,653 | $4.00 | $5.61M | $28.80M | 1 | 2020-07-28 |
| Pandion Therapeutics, Inc. (PAND) Delisted | 10%+ Owner | 1,408,912 | $60.05 | $84.61M | $19.50M | 1 | 2020-07-22 |
| RYTM | 10%+ Owner | 5,210,088 | $92.68 | $482.87M | -$25.47M | 2 | 2020-07-02 |
| Eidos Therapeutics, Inc. (EIDX) Delisted | Director | 1,103,847 | — | — | $18.00M | 4 | 2020-05-29 |
| VSTM | 10%+ Owner | 1,441,946 | $9.94 | $14.33M | -$12.01M | 1 | 2020-04-29 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | 0 | — | — | $32.70M | 7 | 2020-04-03 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 363,587 | $14.59 | $5.30M | $40.00M | 1 | 2020-03-17 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 1,441,070 | $27.00 | $38.91M | $7.22M | 4 | 2017-10-16 |
Recent Filings · Page 8 of 12
114 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-12-14 | SLDB | Grant (A) | +4,938,282 | $18.27M | EDGAR |
| 2020-12-07 | Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-09-23 | DYN | Mixed | +8,415,135 | $37.62M | EDGAR |
| 2020-09-11 | TGTX | Sell (S) | −475,767 | -$12.28M | EDGAR |
| 2020-08-24 | INBX | Conv (C) | +6,387,009 | $0 | EDGAR |
| 2020-07-29 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | +13,251,777 | $81.22M | EDGAR |
| 2020-07-28 | Inozyme Pharma, Inc. (INZY) Delisted | Mixed | +6,010,959 | $28.80M | EDGAR |
| 2020-07-22 | Pandion Therapeutics, Inc. (PAND) Delisted | Mixed | +5,310,069 | $19.50M | EDGAR |
| 2020-07-10 | 89bio, Inc. (ETNB) Delisted | Buy (P) | +1,100,000 | $30.25M | EDGAR |
| 2020-07-02 | RYTM | Sell (S) | −526,324 | -$11.61M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.